[Salmonellosis in HIV infection in a hospital setting in Gabon].
A case-control study was carried out in Libreville, Gabon, to determine the incidence of salmonella infection in HIV patients and identify any special clinical, therapeutic, or prognostic features. The records of 3000 patients hospitalized in the Infectious Disease Department of the Jeanne Ebori Foundation between January 1990 and December 1994 were studied. The incidence of salmonella infection, serotype, clinical presentation, prognostic factors and therapeutic modalities were compared in 2759 HIV-positive patients and 441 HIV-negative patients. Salmonella infection was noted in a total of 208 patients (58 HIV-positive and 150 HIV-negative). The incidence of salmonella infection was 13 p. 100 (non-typhoid in 76 p. 100 of cases) in HIV-positive patients versus 5.4 p. 100 in HIV-negative patients. The predominant serotypes in HIV-positive patients were Salmonella typhimurium and Salmonella enteritidis which accounted 41 p. 100 and 26 p. 100 of the isolated strains. The only significantly difference in clinical presentation was a higher incidence of bacteremia (84 p. 100) and focal lesions (11.4 p. 100) in HIV-positive patients with low-grade salmonella infection. The duration of treatment was three weeks with cotrimoxazole and 10 days with fluoroquinolones and cephalosporines. The outcome in HIV-positive patients was recurrence-free cure in 40 p. 100, multiple relapses in 12 p. 100, and death in 24 p. 100. The remaining patients were lost from follow-up. This study demonstrates the gravity of low-grade salmonella infection in African HIV-positive patients. Early diagnosis is necessary to allow chemotherapy which can be effective despite immunodeficiency.
Okome-Kouakou
M
M
Unité des Maladies Infectieuses, Fondation Jeanne Ebori, Libreville, Gabon.
Bekale
J
J
Kombila
M
M
D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000453:epidemiology; D016022:Case-Control Studies; D002511:Cephalosporins / Q000627:therapeutic use; D005260:Female; D024841:Fluoroquinolones; D005490:Focal Infection / Q000453:epidemiology; D005500:Follow-Up Studies; D005681:Gabon / Q000453:epidemiology; D015658:HIV Infections / Q000453:epidemiology* / Q000628:therapy; D018023:HIV Seronegativity; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D012475:Salmonella / Q000145:classification; D012480:Salmonella Infections / Q000188:drug therapy / Q000453:epidemiology*; D012477:Salmonella enteritidis / Q000145:classification; D012486:Salmonella typhimurium / Q000145:classification; D012703:Serotyping; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D024841:Fluoroquinolones; D015662:Trimethoprim, Sulfamethoxazole Drug Combination